Equities

Bio-Thera Solutions Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Bio-Thera Solutions Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)24.25
  • Today's Change-0.01 / -0.04%
  • Shares traded895.72k
  • 1 Year change+22.47%
  • Beta1.4362
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bio-Thera Solutions Ltd is a China-based company primarily engaged in the research and development of innovative drugs and biosimilars. The Company’s main products include QLETLI (adalimumab), POBEVCY (bevacizumab), TOFIDENCE (tocilizumab), BETAGRIN (bevifibatide citrate) and other products. The Company’s products are mainly used for the treatment of cancer, autoimmune diseases, cardiovascular diseases, ophthalmic conditions, and other illnesses. The Company conducts its business in the domestic and overseas markets.

  • Revenue in CNY (TTM)845.32m
  • Net income in CNY-368.84m
  • Incorporated2003
  • Employees1.17k
  • Location
    Bio-Thera Solutions LtdNo. 18 Spiral 2nd RoadInternational Bio IslandGUANGZHOU 510005ChinaCHN
  • Phone+86 2 032203528
  • Fax+86 2 032203218
  • Websitehttps://www.bio-thera.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Aladdin Biochemical Tech Co Ltd599.98m83.95m5.33bn652.0064.424.99--8.880.24850.24851.783.210.27850.42184.55920,216.305.047.816.908.6062.2160.6118.0924.951.539.150.354148.3332.4420.5515.079.1741.61--
Hangzhou Alltest Biotech Co Ltd881.63m294.76m5.48bn969.0018.551.40--6.213.723.7211.1249.210.20982.386.39909,839.107.0219.187.5721.6655.0057.7933.4738.828.34--0.009335.1414.8329.1367.5030.9971.01--
Bide Pharmatech Co Ltd1.27bn153.31m5.49bn738.0034.352.74--4.321.761.7614.4922.030.51670.88045.251,720,520.006.247.027.528.2943.3042.1612.0713.132.78--0.105548.730.929834.697.17--80.65--
Shouyao Holdings Co Ltd2.14m-206.73m6.04bn178.00--9.23--2,818.82-1.39-1.390.01444.400.00250.03660.262512,033.88-23.67-32.53-27.20-36.2595.7499.43-9,651.03-3,370.016.42--0.0044---24.61-19.34-14.21--49.71--
Jiangsu Yahong Meditech Co Ltd279.02m-362.17m6.93bn391.00--3.91--24.83-0.642-0.6420.49333.100.12511.164.19713,603.90-16.84-14.30-19.15-15.0172.2273.78-134.65-703.804.96--0.1545--1,365.55--4.09--50.48--
GemPharmatech Co Ltd752.70m121.51m7.22bn1.58k58.573.28--9.590.30070.30071.865.370.28074.511.88476,993.404.537.695.428.9661.8468.1716.1425.583.17--0.129521.9410.3928.94-30.8925.8820.02--
Beijing Sun-Novo Pharma Research Co Ltd1.02bn133.01m7.73bn1.36k56.816.65--7.591.211.219.2310.380.474535.481.28653,956.406.0411.3910.4918.8248.6053.3112.7219.661.789.970.335511.2915.7035.80-3.9830.213.50--
Shanghai Medicilon Inc1.08bn-231.86m9.16bn2.27k--4.44--8.49-1.75-1.758.0415.360.37598.561.68459,338.00-8.083.66-9.994.6316.2731.15-21.496.672.19--0.150840.97-24.0118.22-896.21--2.54--
Bio-Thera Solutions Ltd845.32m-368.84m10.05bn1.17k--20.75--11.88-0.8908-0.89082.041.170.37020.77225.96---16.15-16.38-33.76-22.2274.9977.05-43.63-62.110.4617-34.120.573--5.44302.90-29.34--11.14--
HitGen Inc498.51m114.11m12.12bn483.00107.148.24--24.310.28240.28241.243.670.27266.374.691,032,114.006.183.066.873.3655.2353.5522.6714.485.126.590.167434.3214.9910.0826.13-15.653.16--
InventisBio Co Ltd180.53m-116.28m13.55bn185.00--8.14--75.06-0.2012-0.20120.31222.880.0988--1.03975,824.70-6.36-32.89-6.76-35.2299.41---64.41-682.73----0.0127---9.0225.0015.41---3.97--
Data as of Feb 11 2026. Currency figures normalised to Bio-Thera Solutions Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.14%Per cent of shares held by top holders
HolderShares% Held
Penghua Fund Management Co., Ltd.as of 30 Jun 20255.09m1.24%
China Southern Asset Management Co., Ltd.as of 30 Jun 20251.40m0.34%
China Asset Management Co., Ltd.as of 30 Jun 20251.33m0.32%
The Vanguard Group, Inc.as of 07 Jan 20261.06m0.26%
Bosera Asset Management Co., Ltd.as of 30 Jun 2025960.35k0.24%
China Universal Asset Management Co., Ltd.as of 30 Jun 2025940.92k0.23%
Chang Xin Asset Management Co., Ltd.as of 30 Jun 2025591.38k0.15%
GF Fund Management Co., Ltd.as of 30 Jun 2025550.51k0.14%
Rongtong Fund Management Co., Ltd.as of 30 Jun 2025482.49k0.12%
Yinhua Fund Management Co., Ltd.as of 30 Jun 2025445.04k0.11%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.